Immunome Appoints New CMO and Board Members
Ticker: IMNM · Form: 8-K · Filed: Apr 30, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, governance
TL;DR
Immunome beefs up leadership with a new CMO and two board members.
AI Summary
Immunome, Inc. announced on April 24, 2024, the appointment of Dr. P. Ann S. Smith as Chief Medical Officer and the election of Dr. Smith and Dr. Jonathan M. Rothberg to its Board of Directors. Dr. Smith's appointment is effective immediately, and she will also serve as a Class II director. Dr. Rothberg's appointment is also effective immediately, and he will serve as a Class III director.
Why It Matters
The appointment of a new Chief Medical Officer and board members can signal a strategic shift or expansion in the company's leadership and direction, potentially impacting its drug development pipeline and future growth.
Risk Assessment
Risk Level: low — This filing reports on routine corporate governance changes, specifically executive appointments and board elections, which typically carry low immediate risk.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- Dr. P. Ann S. Smith (person) — Appointed Chief Medical Officer and Class II Director
- Dr. Jonathan M. Rothberg (person) — Elected as Class III Director
- April 24, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. P. Ann S. Smith's appointment as Chief Medical Officer?
Dr. P. Ann S. Smith's appointment as Chief Medical Officer is effective immediately as of April 24, 2024.
What class of director will Dr. P. Ann S. Smith serve as?
Dr. P. Ann S. Smith will serve as a Class II director.
Who has been elected as a Class III director?
Dr. Jonathan M. Rothberg has been elected as a Class III director.
When were these appointments and elections reported?
These appointments and elections were reported on April 30, 2024, with the earliest event reported on April 24, 2024.
What is Immunome Inc.'s principal executive office address?
Immunome Inc.'s principal executive office is located at 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011.
Filing Stats: 685 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-04-30 16:01:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
Filing Documents
- tm2413152d1_8k.htm (8-K) — 27KB
- 0001104659-24-054910.txt ( ) — 197KB
- immu-20240424.xsd (EX-101.SCH) — 3KB
- immu-20240424_lab.xml (EX-101.LAB) — 33KB
- immu-20240424_pre.xml (EX-101.PRE) — 22KB
- tm2413152d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date : April 30, 2024 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer